Replies to post #334 on ImmunoGen Inc (IMGN)

[kei]

but the company need money (financing), i think?

[XenaLives]

I think this is a reasonable statement:

I believe IMGN will end the year in double digits as more is known about several drugs they and their partners have in trials. The stock could easily reach highs not seen for a few years if the questions about financing are also resolved either by partnering one or more of their drugs, or by a new major partner utilizing their technology.

50sma crossing 200 sma on daily chart.

Weaker resistance over $3.70 level per VBP. Two gaps down to be filled.



3 day chart looking very solid.